Company Overview More
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of various eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances, and pharmacologically induced mydriasis, as well as that is in Phase II clinical trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
CEO: Sooch M.B.A., MBA, Mina Patel
Market: NASDAQ
Futu Hot List
USHKCN
Trade HeatSearch HeatNews Heat
SymbolLatest Price% Chg

Loading...

Moomoo > Quotes > OCUP Ocuphire Pharma > Detailed Quotes

OCUP Ocuphire Pharma

4.350+0.215+5.20%
Close 11/26 16:55 ET
4.270-0.08-1.84%
Post Mkt Price 11/26 16:59 ET
High
4.650
Open
4.190
Turnover
28.08M
Low
3.970
Prev.Close
4.135
Volume
6.58M
Market Cap
75.26M
P/E(TTM)
Loss
52Wk High
13.812
Shares
17.30M
P/E
Loss
52Wk Low
3.350
H Mkt Cap
53.58M
Bid-Ask Ratio
81.82%
Historical High
13.812
H Shares
12.32M
Vol. Ratio
0.67
Historical Low
3.350
Dividend TTM
--
Div Yield TTM
--
P/B
3.66
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
53.45%
Amplitude
16.45%
Avg Price
4.265
Min Trading Unit
1
Float Market Cap
53.58M
Bid-Ask Ratio
81.82%
Historical High
13.812
Float
12.32M
Vol. Ratio
0.67
Historical Low
3.350
Dividend TTM
--
P/B
3.66
Dividend LFY
--
Turnover Ratio
53.45%
Amplitude
16.45%
Avg Price
4.265
Min Trading Unit
1
Price Forecast

Loading...

News